OMA Guidelines Bundle

Obesity Pharmacotherapy - OMA Obesity Algorithm 2023

Obesity Medicine Association OMA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1349812

Contents of this Issue

Navigation

Page 2 of 29

3 Treatment   ➤ Phentermine is a sympathomimetic amine with possible adrenergic side effects and contraindications in patients with cardiovascular disease. • Phentermine hydrochloride (HCl) 8–37.5 mg prescribed in the U.S. is generally equivalent to 6.4–30 mg of phentermine resin marketed outside the U.S. • Although not consistent with the prescribing information indicated use, phentermine administration for longer than 12 weeks is supported by clinical data and opinion leaders.   ➤ Semaglutide is a GLP-1 RA indicated for BMI ≥30 kg/m 2 + at least 1 obesity-related complication (ORC), BMI ≥27 kg/m 2 , or children with obesity (age ≥12) with a BMI at or above the 95th percentile or ≥85th plus an ORC. It is contraindicated in pregnancy, multiple endocrine neoplasia (MEN) type 2 and a personal or family history of medullary thyroid cancer (CA).   ➤ Liraglutide is a GLP-1 RA approved at 1.8 mg per day for treatment of type 2 diabetes mellitus, and at 3.0 mg per day for treatment of obesity with possible gastrointestinal side effects. It is also indicated for children with obesity (age ≥12) with a BMI at or above the 95th percentile or ≥85th plus an ORC. It is contraindicated in patients with personal or family history of medullary thyroid cancer or Type 2 MEN syndrome.   ➤ Naltrexone/bupropion is a combination of an opioid antagonist and antidepressant, with possible gastrointestinal side effects. It is contraindicated in patients with uncontrolled hypertension, chronic opioid use, seizure disorders, and abrupt discontinuation of alcohol, benzodiazepines, barbiturates and antiepileptic drugs.   ➤ Phentermine/topiramate is a combination of a sympathomimetic amine and anti-seizure/migraine medication with side effects that include paresthesias and dysgeusia. It is contraindicated in women who may become pregnant.   ➤ Liraglutide and phentermine/topiramate can be taken with or without meals.   ➤ Orlistat is a gastrointestinal lipase inhibitor with possible adverse experiences that include oily rectal discharge and flatus. It is contraindicated in patients with chronic malabsorption syndrome and cholestasis.   ➤ Orlistat should be taken three times a day with each meal that contains fat. Bupropion/naltrexone should not be taken with high fat meals due to increased absorption.

Articles in this issue

Archives of this issue

view archives of OMA Guidelines Bundle - Obesity Pharmacotherapy - OMA Obesity Algorithm 2023